International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 731-737 doi: 10.5281/zenodo.16890489
Original Article
To Study the Role of Procalcitonin in Acute Pancreatitis Severity Prediction in Patients Attending a Tertiary Care Centre
 ,
 ,
 ,
 ,
 ,
 ,
 ,
Published
Aug. 17, 2025
Abstract

Background: Acute pancreatitis (AP) is a highly variable inflammatory disorder with clinical presentations ranging from mild, self-limiting illness to severe disease associated with systemic inflammatory response syndrome (SIRS), infected pancreatic necrosis, and multi-organ failure. Early stratification of severity is crucial for timely intervention.

Aim and Objective: To evaluate the diagnostic and prognostic significance of serum procalcitonin (PCT) levels in predicting the severity of acute pancreatitis in patients admitted to a tertiary care centre.

Materials and Methods: A case-control study was conducted on 100 patients, including 50 diagnosed cases of acute pancreatitis and 50 healthy controls. Serum procalcitonin levels were measured within 24 hours of hospital admission. The severity of AP was assessed using the Revised Atlanta Classification. Microbiological samples were collected for culture and sensitivity testing. Associations between PCT levels, severity markers, and microbial isolates were analyzed using statistical tools.

Results: In the present study among 50 AP cases, 34% had isolates of Acinetobacter baumannii, followed by E. coli (24%), Klebsiella pneumoniae (22%), and Pseudomonas aeruginosa (20%). Coinfection with A. baumannii and P. aeruginosa was found in 16% of patients. PCT levels were significantly elevated in patients with infected necrosis, systemic complications, and those requiring ICU admission. PCT >0.5 ng/mL was significantly associated with severe AP and multiorgan failure (p<0.05).

Conclusion: Serum procalcitonin is a reliable biomarker for early prediction of AP severity and infection-related complications. It may supplement clinical scores for better risk stratification and management.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1888 Views
193 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved